Less PSA testing minimizes overdiagnosis but may lead to increase in metastatic prostate cancer cases

By | April 24, 2022
Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer.